Oncocyte

OCX47

Penny Stock

$2.88arrow_drop_down3.03%-$0.09

Penny Stock

OCX47

$2.88

arrow_drop_down3.03%-$0.09

Penny Stock

Performance History

Key Stats
Open	$2.93
Prev. Close	$2.97
EPS	-4.28
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$40.10M
PE Ratio	-

	LOW	HIGH
Day Range	2.84	2.98
52 Week Range	2.08	4.34

Ratios







EPS	-4.28

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Oncocyte (OCX)

Oncocyte Corp (OCX) is a leading biotechnology company specializing in precision diagnostics for oncology. With a focus on developing innovative diagnostic tests, Oncocyte aims to revolutionize cancer treatment by providing personalized and targeted therapies. The company's flagship product is the DetermaRx test, a novel gene expression assay that predicts the risk of recurrence in early-stage lung cancer patients. This groundbreaking test enables oncologists to identify patients who would benefit from adjuvant chemotherapy, while sparing those who would not.

In addition to DetermaRx, Oncocyte has a robust pipeline of diagnostic tests in various stages of development. These tests target a wide range of cancers, including breast, colon, and bladder cancer. The company's expertise lies in utilizing advanced genomic and proteomic technologies to identify biomarkers that are indicative of disease progression and treatment response. Oncocyte's innovative approach has garnered significant attention from the medical community and has the potential to transform cancer care.

Websitecall_made

Sector: Healthcare
Industry: Diagnostics & Research
CEO: Mr. Joshua Riggs
Headquarters: Irvine
Employees: 75
Exchange: NASDAQ

Keep an eye on Oncocyte

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Oncocyte's (OCX) price per share?

The current price per share for Oncocyte (OCX) is $2.88. The stock has seen a price change of -$0.09 recently, indicating a -3.03% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Oncocyte (OCX)?

For Oncocyte (OCX), the 52-week high is $4.34, which is 50.69% from the current price. The 52-week low is $2.08, the current price is 38.46% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Oncocyte (OCX) a growth stock?

Oncocyte (OCX) has shown an average price growth of 0.41% over the past three years. It has received a score of -1 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Oncocyte as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Oncocyte (OCX) stock price performance year to date (YTD)?

As of the latest data, Oncocyte (OCX) has a year-to-date price change of -12.73%. Over the past month, the stock has experienced a price change of -8.36%. Over the last three months, the change has been -2.37%. Over the past six months, the figure is -3.36%. Looking at a longer horizon, the five-year price change stands at -93.14%.

help

Is Oncocyte (OCX) a profitable company?

Oncocyte (OCX) has a net income of -$27.78M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 33.33% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -5.45K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.5M, with a revenue growth rate of 56.89%, providing insight into the company's sales performance and growth. The gross profit is $501K. Operating income is noted at -$22.86M. Furthermore, the EBITDA is -$20.22M.

help

What is the market capitalization of Oncocyte (OCX)?

Oncocyte (OCX) has a market capitalization of $40.11M. The average daily trading volume is 17.41K, indicating the stock's liquidity and investor engagement.